This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of epoetin alfa: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of epoetin alfa: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Epoetin alfa has been shown to be effective in treating anemia in a variety of patient populations, including those with chronic kidney disease (CKD), cancer, and HIV infection. 13 , 9 , 4 , 5 , 10 , 14 , 1 , 23 , 16 , 2 , 19 , 21 , 7 , 8 , 3 , 17 , 24 , 28 , 25 , 11 , 6 , 26 , 12 , 22 , 18 . Epoetin alfa has been shown to increase hemoglobin levels, reduce the need for blood transfusions, and improve quality of life. 13 , 9 , 4 , 5 , 10 , 14 , 1 , 23 , 16 , 2 , 19 , 21 , 7 , 8 , 3 , 17 , 24 , 28 , 25 , 11 , 6 , 26 , 12 , 22 , 18 . Epoetin alfa may also be effective in preventing anemia in cancer patients undergoing chemotherapy. 9 , 4 , 10 , 14 , 7 , 8 , 23 , 21 , 7 , 22 . In patients undergoing orthopedic surgery, epoetin alfa has been shown to reduce the need for blood transfusions. 1 , 2 , 25 .

Benefits and Risks

Benefit Summary

Epoetin alfa has been shown to have the following benefits in treating anemia: 13 , 9 , 4 , 5 , 10 , 14 , 1 , 23 , 16 , 2 , 19 , 21 , 7 , 8 , 3 , 17 , 24 , 28 , 25 , 11 , 6 , 26 , 12 , 22 , 18

  • Increased hemoglobin levels
  • Reduced need for blood transfusions
  • Improved quality of life

Risk Summary

Epoetin alfa has been shown to have the following risks: 10 , 8 , 11 , 17

  • Increased risk of blood clots
  • Increased risk of high blood pressure
  • Increased risk of heart disease
  • Increased risk of stroke
  • Increased risk of death

Comparison of Studies

Similarities between Studies

Many studies have shown that epoetin alfa is effective in treating anemia. 13 , 9 , 4 , 5 , 10 , 14 , 1 , 23 , 16 , 2 , 19 , 21 , 7 , 8 , 3 , 17 , 24 , 28 , 25 , 11 , 6 , 26 , 12 , 22 , 18 . Epoetin alfa has also been shown to be effective in preventing anemia in cancer patients undergoing chemotherapy. 9 , 4 , 10 , 14 , 7 , 8 , 23 , 21 , 7 , 22 . In patients undergoing orthopedic surgery, epoetin alfa has been shown to reduce the need for blood transfusions. 1 , 2 , 25 .

Differences between Studies

The dosage, route of administration, patient population, and outcome measures varied across studies, making direct comparisons difficult. Some studies have suggested that epoetin alfa may have an impact on survival, but this requires further investigation. 7 , 8 .

Consistency and Contradictions in Results

While many studies have demonstrated the effectiveness of epoetin alfa in treating anemia, some studies suggest a potential impact on survival. 7 , 8 . Further research is needed to clarify this potential link.

Important Considerations for Real-Life Applications

While epoetin alfa is an effective treatment for anemia, it is crucial to follow your doctor's instructions carefully due to the risks of blood clots and other complications. 10 , 8 , 11 , 17 . Remember that epoetin alfa is not a cure-all for all types of anemia and may not be effective for everyone. Consult your physician to determine the most appropriate treatment for your individual needs.

Limitations of Current Research

Direct comparison of research findings on epoetin alfa can be challenging due to varying patient populations, dosages, routes of administration, and outcome measures. Further research is needed to clarify the potential impact of epoetin alfa on survival. 7 , 8 .

Future Research Directions

Additional research is needed to explore the long-term effects and safety of epoetin alfa, especially its potential impact on survival. Larger clinical trials are needed to investigate this area. 7 , 8 . Further investigation into optimal dosing strategies and administration methods is also warranted.

Conclusion

Epoetin alfa is an effective treatment option for anemia, but it is crucial to follow your doctor's instructions closely due to potential side effects and risks. 10 , 8 , 11 , 17 . Consult your physician to discuss the most appropriate treatment plan for your individual needs.


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 28 papers
Positive Content
25
Neutral Content
3
Negative Content
0
Article Type
21
3
3
6
28

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: FokkemaMarieke L, KleijnLennaert, van der MeerPeter, BelonjeAnne M, AchterhofSandra K, HillegeHans L, van 't HofArnoud, JukemaJ Wouter, PeelsHans O, HenriquesJosé P, ten BergJurriën M, VosJeroen, van GilstWiek H, van VeldhuisenDirk J, VoorsAdriaan A


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.